TerminatedNCT02726659

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Medication studyAges 18–45CanadaBipolarity

The study in practice

Understand this study

This study is for people with bipolarity. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: May 2016

Recruitment status: Terminated
Enrollment listed in the registry: 1
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor type: Research institute
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Canada
Age range: From 18 Years to 45 Years
Official registry ID: NCT02726659
Official title: Show the full official title
Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression: a Randomized, Double-blind, Placebo-controlled Trial

Terminated

London

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Celecoxib and Placebo.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.